Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance

Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a devastating malignancy with a poor prognosis. The combination of cisplatin (CDDP) plus cetuximab (CX) is one of the standard first-line treatments in this disease. However, this therapeutic regimen is often associated with h...

Full description

Bibliographic Details
Main Authors: Federica Iannelli, Andrea Ilaria Zotti, Maria Serena Roca, Laura Grumetti, Rita Lombardi, Tania Moccia, Carlo Vitagliano, Maria Rita Milone, Chiara Ciardiello, Francesca Bruzzese, Alessandra Leone, Ernesta Cavalcanti, Rossella De Cecio, Giuseppina Iachetta, Salvatore Valiante, Franco Ionna, Francesco Caponigro, Elena Di Gennaro, Alfredo Budillon
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
HDAC inhibitor
valproic acid
cisplatin
cetuximab
epidermal growth factor receptor
head and neck squamous cell carcinoma
Online Access:https://www.frontiersin.org/article/10.3389/fcell.2020.00732/full

Internet

https://www.frontiersin.org/article/10.3389/fcell.2020.00732/full

Similar Items